Viatris Secures Multiple FDA and PMDA Approvals for Long-Acting and Hormonal Treatment Pipeline

Healthcare company Viatris Inc. (VTRS) revealed significant regulatory progress across its pharmaceutical portfolio, marking a productive quarter for the organization's global development initiatives. The company has achieved a series of approvals and acceptances from major regulatory bodies that span injectable generics, contraceptive solutions, and rare disease therapies.

**Generic Injectable Formulation Approved**

In a major win for its generic medications division, the FDA has greenlit Viatris' octreotide acetate injectable suspension, which serves as a bioequivalent alternative to the branded Sandostatin LAR Depot formulation. This long-acting injectable is designed to manage symptoms associated with rare endocrine disorders, particularly acromegaly. The approval represents the company's fourth injectable authorization from the FDA during the current year, alongside previous clearances for iron sucrose, paclitaxel, and liposomal amphotericin B formulations.

**Weekly Transdermal Contraceptive Advancement**

The regulatory pathway for Viatris' innovative hormonal contraceptive has progressed favorably, with the FDA accepting its New Drug Application for a weekly transdermal patch delivery system. The formulation contains 150 mcg of norelgestromin combined with 17.5 mcg of ethinyl estradiol, representing a low-dose hormonal approach. The agency has assigned a targeted review completion date of July 30, 2026. This non-invasive reversible contraceptive option targets women of childbearing age with a BMI below 30 kg/m² who seek convenient hormonal birth control alternatives to daily oral medications.

**Rare Eye Disease Investigational Program**

The FDA has issued clearance for Viatris' investigational new drug application covering MR-146, an adeno-associated virus gene therapy candidate utilizing an enriched tear film technology platform. This therapeutic approach specifically addresses neurotrophic keratopathy, a degenerative corneal condition affecting approximately 73,000 individuals in the United States. The disease progressively damages corneal tissue and can lead to sight-threatening complications. Clinical evaluation is anticipated to commence during the first half of 2026, with the Phase 1/2 trial designated as CORVITA.

**Japanese Market Authorization for Sleep Disorder Treatment**

The Japan Pharmaceuticals and Medical Devices Agency has accepted Viatris' regulatory submission for pitolisant in treating obstructive sleep apnea syndrome. The company expects to file its Japanese new drug application for narcolepsy indications by year-end. Supporting data from Phase 3 clinical studies conducted in Japanese patient populations demonstrated meaningful efficacy outcomes. Patients administered pitolisant showed statistically significant reductions in excessive daytime sleepiness measurements using the Epworth Sleepiness Scale compared to placebo recipients (p=0.007), despite concurrent CPAP therapy utilization.

In pre-market trading activity, VTRS stock was quoted at $11.66, reflecting a 0.34% decline on the Nasdaq exchange.